Pathobiology of biliary epithelia and cholangiocarcinoma: Proceedings of the Henry M. and Lillian Stratton Basic Research Single-Topic Conference

Hepatology

Volumn 48, Issue 6, 2008, Pages 2040-2046

  Sirica, Alphonse E ^a   Nathanson, Michael H ^b   Gores, Gregory J ^c   LaRusso, Nicholas F ^d  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

^d Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN MCL 1; RAF PROTEIN; VASCULOTROPIN;

BILE DUCT CARCINOMA; CANCER GROWTH; CARCINOGENESIS; CELL FUNCTION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSPORT; CONFERENCE PAPER; EPITHELIUM; EPITHELIUM CELL; HEPATOBILIARY SYSTEM; HUMAN; LIVER CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN TARGETING; SIGNAL TRANSDUCTION; STEM CELL EXPANSION; BILE DUCT TUMOR; INTERNATIONAL COOPERATION; INTRAHEPATIC BILE DUCT; PATHOLOGY; UNITED STATES;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BILIARY TRACT; CELL PROLIFERATION; CHOLANGIOCARCINOMA; EPITHELIUM; GEORGIA; HUMANS; INTERNATIONAL COOPERATION;

EID: 58149401287     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22623     Document Type: Conference Paper

References (56)

1. Kodama Y, Hijkata M, Kageyama R, Shimotohno K, Chiba T. The role of Notch signaling in the development of intrahepatic bile ducts. Gastroenterology 2004;127:1775-1786.
2. Loomes KM, Russo P, Ryan M, Nelson A, Underkoffler L, Glover C, et al. Bile duct proliferation in liver-specific Jag1 conditional knockout mice: effects of gene dosage. HEPATOLOGY 2007;45: 323-330.
3. Lozier J, McCright B, Gridley T. Notch signaling regulates bile duct morphogenesis in mice. PLoS ONE 2008;3:e1851.
4. Clotman F, Lannoy VJ, Reber M, Cereghini S, Cassiman D, Jacquemin P, et al. The onecut transcription factor HNF6 is required for normal development of the biliary tract. Development 2002;129:1819-1828.
5. Costa RH, Kalinichenko VV, Holterman A-XL, Wang X. Transcription factors in liver development, differentiation, and regeneration. HEPATOLOGY 2003;38:1331-1347.
6. Yamasaki H, Sada A, Iwata T, Niwa T, Tomizawa M, Xanthopoulos KG, et al. Suppression of C/EBPα expression in periportal hepatoblasts may stimulate biliary cell differentiation through increased Hnf6 and Hnf1b expression. Development 2006;133:4233-4243.
7. Wang M, Tan Y, Costa RH, Holterman A-XL. In vivo regulation of murine CYP7A1 by HNF-6: a novel mechanism for diminished CYP7A1 expression in biliary obstruction. HEPATOLOGY 2004;40:600-608.
8. Lorent K, Yeo SY, Oda T, Chandrasekharappa S, Chitnis A, Matthews RP, et al. Inhibition of Jagged-mediated Notch signaling disrupts zebrafish biliary development and generates multi-organ defects compatible with an Alagille syndrome phenocopy. Development 2004;131:5753-5766.
9. Matthews RP, Lorent K, Russo P, Pack M. The zebrafish onecut gene hnf-6 functions in an evolutionarily conserved genetic pathway that regulates vertebrate biliary development. Dev Biol 2004;274:245-259.
10. Katoonizadeh A, Nevens F, Verslype C, Pirenne J, Roskams T. Liver regeneration in acute severe liver impairment: a clinicopathological correlation study. Liver Int 2006;26:1225-1233.
11. Hu M, Kurobe M, Jeong YJ, Fuerer C, Ghole S, Nusse R, et al. Wnt/ β-catenin signaling in murine hepatic transit amplifying progenitor cells. Gastroenterology 2007;133:1579-1591.
12. Yang W, Yan HX, Chen L, Liu Q, He YQ, Yu LX, et al. Wnt/β-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Cancer Res 2008;68:4287-4295.
13. Crosby HA, Nijjar SS, deGoyet JV, Kelly DA, Strain AJ. Progenitor cells of the biliary epithelial cell lineage. Semin Cell Dev Biol 2002;13:397-403.
14. Jensen CH, Jauho EI, Santoni-Rugiu E, Holmskov U, Teisner B, Tygstrup N, et al. Transit-amplifying ductular (oval) cells and their hepatocytic progeny are characterized by a novel and distinctive expression of delta-like protein/preadipocyte factor1/fetal antigen 1. Am J Pathol 2004;164:1347-1359.
15. Limaye PB, Alarcón G, Walls AL, Nalesnik MA, Michalopoulos GK, Demetris AJ, et al. Expression of specific hepatocyte and cholangiocyte transcription factors in human liver disease and embryonic development. Lab Invest 2008;88:865-872.
16. Libbrecht L. Hepatic progenitor cells in human liver tumor development. World J Gastroenterol 2006;12:6261-6265.
17. Nishikawa Y, Doi Y, Watanabe H, Tokairin T, Omori Y, Su M, et al. Transdifferentiation of mature rat hepatocytes into bile duct-like cells in vitro. Am J Pathol 2005;166:1077-1088.
18. Limaye PB, Bowen WC, Orr AV, Luo J, Tseng GC, Michalopoulos GK. Mechanisms of hepatocyte growth factor-mediated and epidermal growth factor-mediated signaling in transdifferentiation of rat hepatocytes to biliary epithelium. HEPATOLOGY 2008;47:1702-1713.
19. Watanabe H, Hata M, Terada N, Ueda H, Yamada N, Yamanegi K, et al. Transdifferentiation into biliary ductular cells of hepatocytes transplanted into the spleen. Pathology 2008;40:272-276.
20. Rygiel KA, Robertson H, Marshall HL, Pekalski M, Zhao L, Booth TA, et al. Epithelial-mesenchymal transition contributes to portal tract fibrogenesis during human chronic liver disease. Lab Invest 2008;88:112-123.
21. Simper-Ronan R, Brilliant K, Flanagan D, Carreiro M, Callanan H, Sabo E, et al. Cholangiocyte marker-positive and -negative fetal liver cells differ significantly in their ability to regenerate the livers of adult rats exposed to retrorsine. Development 2006;133:4269-4279.
22. Castillo GD, Álvarez-Barrientos A, Carmona-Cuenca I, Fernández M, Sánchez A, Fabregat I. Isolation and characterization of a putative liver progenitor population after treatment of fetal rat hepatocytes with TGFbeta. J Cell Physiol 2008; 215:846-855.
23. Ochsner SA, Strick-Marchand H, Qui Q, Venable S, Dean A, Wilde M, et al. Transcriptional profiling of bipotential embryonic liver cells to identify liver progenitor cell surface markers. Stem Cells 2007;25:2476-2487.
24. Hixson DC, Brown J, McBride AC, Affigne S. Differentiation status of rat ductal cells and ethionine-induced hepatic carcinomas defined with surface-reactive monoclonal antibodies. Exp Mol Pathol 2000;68:152-169.
25. Salter KD, Fitz JG, Roman RM. Domain-specific purinergic signaling in polarized rat cholangiocytes.AmJ Physiol Gastrointest Liver Physiol 2000; 278:G492-G500.
26. Shibao K, Hirata K, Robert ME, Nathanson MH. Loss of inositol 1, 4, 5-triphosphate receptors from bile duct epithelia is a common event in cholestasis. Gastroenterology 2003;125:1175-1187.
27. Minagawa N, Nagata J, Shibao K, Masyuk AI, Gomes DA, Rodrigues M, et al. Cyclic AMP regulates bicarbonate secretion in cholangiocytes through release of ATP into bile. Gastroenterology 2007;133:1592-1602.
28. Fiorotto K, Spirlì C, Fabris L, Cadamuro M, Okolicsanyi L, Strazzabosco M. Ursodeoxycholic acid stimulates cholangiocytes fluid secretion in mice via CFTR-dependent ATP secretion. Gastroenterology 2007;133:1603-1613.
29. Gradilone SA, Masyuk AI, Splinter PL, Banales JM, Huang BQ, Tietz PS, et al. Cholangiocyte cilia express TRPV4 and detect changes in luminal tonicity including bicarbonate secretion. Proc Natl Acad Sci U S A 2007; 104:19138-19143.
30. Masyuk AI, Masyuk TV, LaRusso NF. Cholangiocyte primary cilia in liver health and disease. Dev Dyn 2008;237:2007-2012.
31. Alvaro D, Mancino MG, Glaser S, Gaudio E, Marzioni M, Francis H, et al. Proliferating cholangiocytes: a neuroendocrine compartment in the diseased liver. Gastroenterology 2007;132:415-431.
32. Marzioni M, Fava G, Alvaro D, Alpini G, Benedetti A. Control of cholangiocyte adaptive responses by visceral hormones and neuropeptides. Clin Rev Allergy Immunol 2008. PMID.18548352. DOI: 10.1007/ S12016-008-8090-1.
33. Mack CL, Tucker RM, Lu BR, Sokol RJ, Fontenot AP, Ueno Y, et al. Cellular and humoral autoimmunity directed at bile duct epithelia in murine biliary atresia. HEPATOLOGY 2006;44:1231-1239.
34. Harada K, Nakanuma Y. Biliary innate immunity and cholangiopathy. Hepatol Res 2007;37:S430-S437.
35. Chen XM, O'Hara SP, LaRusso NF. The immunobiology of cholangiocytes. Immunol Cell Biol 2008;86:497-505.
36. Everson GT, Taylor MR, Doctor RB. Polycystic disease of the liver. HEPATOLOGY 2004;40:774-782.
37. Masyuk T, LaRusso N. Polycystic liver disease: new insights into disease pathogenesis. HEPATOLOGY 2006;43:906-908.
38. Karlsson-Rosenthal C, Millar JD. Cdc25: mechanisms of checkpoint inhibition and recovery. Trends Cell Biol 2006;16:285-292.
39. Fabris L, Cadamuro M, Fiorolto R, Roskams T, Spirlì C, Melero S, et al. Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases. HEPATOLOGY 2006;43:1001-1012.
40. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004;24:115-125.
41. McGlynn KA, Tarone RE, El-Serag HB. A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiol Biomarkers Prev 2006;15: 1198-1203.
42. Ben-Menachem T. Risk factors for cholangiocarcinoma. Eur J Gastroenterol Hepatol 2007;19:615-617.
43. Berthiaume EP, Wands J. The molecular pathogenesis of cholangiocarcinoma. Semin Liver Dis 2004;24:127-137.
44. Wu T. Cyclooxygenase-2 and prostaglandin signaling in cholangiocarcinoma. Biochim Biophys Acta 2005;1755:135-150.
45. Matsumura N, Yamamoto M, Aruga A, Takasaki K, Nakano M. Correlation between expression of MUC1 core protein and outcome after surgery in mass-forming intrahepatic cholangiocarcinoma. Cancer 2002;94:1770-1776.
46. Shibahara H, Tamada S, Higashi M, Goto M, Batra SK, Hollingsworth MA, et al. MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type. HEPATOLOGY 2004;39: 220-229.
47. Singh PK, Hollingsworth MA. Cell surface-associated mucins in signal transduction. Trends Cell Biol 2006;16:467-476.
48. Maeda T, Taguchi K, Aishima S, Shimada M, Hintz D, LaRusso N, et al. Clinicopathological correlates of aspartyl (asparaginyl) β-hydroxylase overexpression in cholangiocarcinoma. Cancer Detect Prev 2004;28:313-318.
49. Chen Y, Xu J, Jhala N, Pawar P, Zhu ZB, Ma L, et al. Fas-mediated apoptosis in cholangiocarcinoma cells is enhanced by 3, 3′ diindolylmethane through inhibition of AKT signaling and FLICE-like inhibitory protein. Am J Pathol 2006;169:1833-1842.
50. Isomoto H, Mott JL, Kobayashi S, Werneburg NW, Bronk SF, Haan S, et al. Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology 2007;132:384-396.
51. Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell J, et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006;130: 2113-2129.
52. Meng F, Wehbe-Janek H, Henson R, Smith H, Patel T. Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes. Oncogene 2008;27:378-386.
53. Tang D, Nagano H, Yamamoto H, Wada H, Nakamura M, Kondo M, et al. Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoeitin-1/2, thrombospondin-1 and clinicopathological significance. Oncol Rep 2006;15:525-532.
54. Thomas MB. Biological characteristics of cancers in the gallbladder and biliary tract and targeted therapy. Crit Rev Oncol Hematol 2007;61:44-51.
55. Sirica AE, Zhang Z, Lai G-H, Asano T, Shen X-N, Ward DJ, et al. A novel "patient-like" model of cholangiocarcinoma progression based on bile duct inoculation of tumorigenic rat cholangiocyte cell lines. HEPATOLOGY 2008;47:1178-1190.
56. Xu X, Kobayashi S, Qiao W, Li C, Xiao C, Radaeva S, et al. Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest 2006;116:1843-1852.